There are (as ever) lots of contingencies here -- but the central one, for Tim Anderson, at least, is whether BMS and Opdivo
® will be able to stop their ongoing lung cancer Phase II trial early -- and win a broad FDA approval, and do so earlier than Merck might by say mid-2015. Still, it is a
very nice vote of confidence from Bernstein & Co.
Here's
the bit:
. . . .Merck was upgraded by equities research analysts at Sanford C. Bernstein to an “outperform” rating in a research note issued to investors on Monday. . . .
Kenilworth's NYSE price edged up on this news. And, we will -- of course -- keep you posted. Now, stay warm out there!
No comments:
Post a Comment